Board of Directors
The Board consists of the ordinary members: Gisela Sitbon (Chairman), Laura Chirica, Henrik Didner, Rolf Ehrnström, Ted Elvhage and Simon Turner. The Board is elected annually at the Annual General Meeting for the period until the next Annual General Meeting has been held.
Gisela Sitbon, PhD
Chairman since 2020
Gisela Sitbon has a research background within molecular biology, combined with more than 25 years of senior level experience from the life science industry. This includes business development and operational positions, as well as co-founding and managing a service-providing diagnostic company, later acquired by Capio. Currently holds several chair positions and board appointments in private and stock market listed companies.
Education: Doctor of Medical Sciences (PhD), Karolinska Institutet.
Previous experience: Board work in public, private and owner-managed companies. Sowing and growth financing in the Life Science sector. Entrepreneur, CEO and leading positions, such as business development, R&D and quality management systems, in innovative Life Science companies.
Other assignments: Gisela Sitbon is Chairman of the Board of Enginzyme AB and Nanologica AB and a Board member of Annexin Pharmaceuticals AB, Encare AB and In Singulo AB.
Holding: 6,000 shares
Gisela Sitbon is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.
Henrik Didner, PhD
Director since 2018
Co-founder, owner and working chairman of the Swedish leading fund management firm Didner & Gerge. Other current commitments include the position as chairman for Uppsala University Holding. Henrik Didner holds a PhD in Business Administration from Uppsala University.
Education: Doctor of Economics (PhD), Uppsala University.
Previous experience: Fund management since 1994.
Other assignments: Chairman of the Board of Uppsala University Invest AB, Monesi AB and Hebeas AB. Board member of G-Förvaltning AB, Axel Johansson Uppsala Nya Tidning Förvaltning AB, CLA Sweden AB, Baracken AB, Diga AB, Emitis AB and VBN Components AB. Board member and Deputy CEO of Didner & Gerge Fonder AB.
Holding: 2,282,436 shares (via Monesi Förvaltnings AB).
Henrik Didner is independent in relation to the Company and the company management, but is not independent in relation to the Company’s major shareholders.
Director since 2020
Rolf Ehrnström has extensive R&D leadership experience from biotech and diagnostic companies like e.g. Amersham Pharmacia Biotech, Dako (acquired by Agilent) and the microfluidics pioneer company Gyros. Today, Rolf Ehrnström serves on the board of directors for various innovation-driven life science companies and is appointed independent partner at Ventac Partners.
Education: Master of Science in Biochemistry and Biotechnology from KTH Stockholm.
Previous experience: 20 years in leading positions in R&D at Pharmacia Biotech, VP R&D at Gyros AB and CVP R&D at Dako A/S.
Other assignments: Board member of Scandinavian Chemotech AB, Fluimedix A/S, ZipPrime Oy and Saga Diagnostics AB, in addition to being partner at Ventac Partners. Active as a consultant within life science and a member of various foundations (Vinnova, EITH, NOME, and Uppsala Bio-X).
Holding: 9,878 shares (via Reomics AB)
Rolf Ehrnström is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.
Laura Chirica, PhD
Director since 2021
Laura Chirica holds an PhD in biochemistry and has over 20 years’ experience of global commercial positions in the bioprocess, biotech and diagnostics sector. In her previous role as Chief Commercial Officer for Immunovia, she played a key role in the commercialization of Immunovias first product and the company’s journey to the market. She is also a board member in Senzagen which develops and sells state of the art non animal tests for assessing a substance’s allergenicity.
Education: Doctor of Biochemistry (PhD), Umeå University.
Previous experience: CCO for Immunovia AB, VP Sales and Marketing at Euro Diagnostica AB, Director Purification Technologies Europe at Sartorius Stedim, Global Marketing Director at Dako A/S and Global Marketing Program Manager at GE Healthcare.
Other assignments: Board member of SenzaGen AB.
Holding: 5,628 shares
Laura Chirica is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.
Hilja Ibert, PhD
Director since 2023
Hilja Ibert brings more than 30 years of experience from the clinical diagnostics industry at international companies like Hologic, Becton Dickinson and bioMérieux, including Vice President and General Manager positions within the business areas of Diagnostic systems and Bioscience. She is currently CEO of Gentian Diagnostics, a Norwegian publicly listed company having products on the international immunodiagnostics market.
Education: Dr. Oec. troph (PhD) with doctoral on Industrial and Clinical Microbiology, Rheinische Friedrich Wilhelms University of Bonn.
Previous experience: More than 30 years within the clinical diagnostics industry including CEO of miDiagnostics, VP/GM positions at Hologic and Becton Dickinson, Corporate Marketing Manager at bioMérieux.
Other assignments: CEO of Gentian Diagnostics ASA, Norway.
Hilja Ibert is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.
Nedal Safwat, PhD
Director since 2023
Nedal Safwat is an accomplished leader in the clinical diagnostic industry with 20+ years of global experience. Nedal Safwat has held diverse roles, gaining a comprehensive understanding of the industry. He has successfully led commercial teams, developing strategies for microbiology applications such as bacterial identification, antibiotic susceptibility testing, resistance, and sepsis detection.
Education: Doctor of Biochemistry (PhD), North Carolina State University.
Previous experience: VP Marketing and Business Development at Chromacode Inc, Executive Director, Director of Global Marketing and Director of Clinical Marketing at bioMérieux.
Other assignments: VP and Head of Molecular Diagnostics North America at Qiagen, US.
Nedal Safwat is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.
Next-generation antimicrobial susceptibility testingTake a look at our E-book